Mallinckrodt has launched a retrospective study to collect real-world data on its nitric gas inhaled therapy, INOmax, as a potential treatment for COVID-19 patients with respiratory problems.

The company is partnering with research company Pharmerit International to gather data from 200 hospitalized coronavirus adult patients treated with INOmax from Jan. 1 to July 31. The patient data will be assessed for 30 days following their discharge.

“We hope this retrospective chart review will help to further extend our understanding of the use of inhaled nitric oxide,” the company said.

INOmax is approved in Europe for treating respiratory failure linked with pulmonary hypertension, or high blood pressure in the lungs, but has not been evaluated or approved by the FDA.